A critical review of five different targeted therapy approaches at ASCO
Can we scale new heights with next generation anti-cancer agents?
One of the fascinating things about ASCO is how early new product development readouts outside of ‘hot’ names (or stock tickers) can often be ignored, forgotten, or simply dismissed as me-toos with seemingly comparable data.
The thing is, two people can look at a mountain and see it differently, much like five blindfolded people might describe various aspects of an elephant based on their perceptions of what’s in front of them – imagine what a tail versus a trunk or ear might produce, for example.
This is also particularly true with targeted therapies, which are undergoing something of a renaissance of late.
In this post, we look at five targets (and tumour types) where we are seeing some solid progress either with single agent therapy or with combination approaches, some of which – be warned – are rather controversial…
To continue reading our latest discussion on oncology new product development plus commentary and analysis BSB subscribers can log-in or you can click to access the content.
This content is restricted to subscribers
